BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gertz MA, Kyle RA. Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients. Am J Med. 1988;85:73-80. [PMID: 3389383 DOI: 10.1016/0002-9343(88)90505-0] [Cited by in Crossref: 84] [Cited by in F6Publishing: 65] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Nowak G, Westermark P, Wernerson A, Herlenius G, Sletten K, Ericzon B. Liver transplantation as rescue treatment in a patient with primary AL kappa amyloidosis. Transplant Int 2000;13:92-7. [DOI: 10.1111/j.1432-2277.2000.tb01047.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
2 Milani P, Basset M, Russo F, Foli A, Palladini G, Merlini G. The lung in amyloidosis. Eur Respir Rev 2017;26:170046. [DOI: 10.1183/16000617.0046-2017] [Cited by in Crossref: 54] [Cited by in F6Publishing: 32] [Article Influence: 13.5] [Reference Citation Analysis]
3 Gertz MA, Kyle RA. Amyloidosis: prognosis and treatment. Semin Arthritis Rheum. 1994;24:124-138. [PMID: 7839154 DOI: 10.1016/s0049-0172(05)80006-x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 7] [Article Influence: 3.1] [Reference Citation Analysis]
4 Weiler CR, Bankers-fulbright JL. Common Variable Immunodeficiency: Test Indications and Interpretations. Mayo Clinic Proceedings 2005;80:1187-200. [DOI: 10.4065/80.9.1187] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
5 Segev A, Manor Y, Bernheim J, Mekori YA. Light chain myeloma presenting as severe obstructive jaundice due to hepatic amyloidosis. Eur J Haematol 1999;63:364-5. [PMID: 10580572 DOI: 10.1111/j.1600-0609.1999.tb01143.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Linardaki G, Drivas G, Archimandritis A. AL-Type Amyloidosis Presenting with Rapidly Deteriorating Liver Involvement: . Journal of Clinical Gastroenterology 1997;24:297-8. [DOI: 10.1097/00004836-199706000-00033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Bion E, Brenard R, Pariente EA, Lebrec D, Degott C, Maitre F, Benhamou JP. Sinusoidal portal hypertension in hepatic amyloidosis. Gut 1991;32:227-30. [PMID: 1864548 DOI: 10.1136/gut.32.2.227] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
8 Venkatesh SK, Hoodeshenas S, Venkatesh SH, Dispenzieri A, Gertz MA, Torbenson MS, Ehman RL. Magnetic Resonance Elastography of Liver in Light Chain Amyloidosis. J Clin Med 2019;8:E739. [PMID: 31126105 DOI: 10.3390/jcm8050739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lachmann HJ, Hawkins PN. Amyloidosis and the lung. Chron Respir Dis 2006;3:203-14. [DOI: 10.1177/1479972306070066] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 7.2] [Reference Citation Analysis]
10 Kumar KS, Lefkowitch J, Russo MW, Hesdorffer C, Kinkhabwala M, Kapur S, Emond JC, Brown RS. Successful sequential liver and stem cell transplantation for hepatic failure due to primary AL amyloidosis. Gastroenterology. 2002;122:2026-2031. [PMID: 12055607 DOI: 10.1053/gast.2002.33648] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
11 Russo P, Palladini G, Foli A, Zenone Bragotti L, Milani P, Nuvolone M, Obici L, Perfetti V, Brugnatelli S, Invernizzi R, Merlini G. Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients. Amyloid 2011;18 Suppl 1:92-3. [PMID: 21838445 DOI: 10.3109/13506129.2011.574354033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
12 Nair AV, Yadav MK, Unni MN, Simi CM, Biji KA, Manoj KS, Ali S, Nair AK. Hepatic Amyloidosis: Something That Can camouflage and Deceive our Perception! Indian J Med Paediatr Oncol 2017;38:236-9. [PMID: 28900341 DOI: 10.4103/ijmpo.ijmpo_46_16] [Reference Citation Analysis]
13 Hilscher MB, Kamath PS. The Liver in Circulatory Disturbances. Clinics in Liver Disease 2019;23:209-20. [DOI: 10.1016/j.cld.2018.12.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Sonthalia N, Jain S, Pawar S, Zanwar V, Surude R, Rathi PM. Primary hepatic amyloidosis: A case report and review of literature. World J Hepatol 2016; 8(6): 340-344 [PMID: 26962400 DOI: 10.4254/wjh.v8.i6.340] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
15 Petre S, Shah IA, Gilani N. Review article: gastrointestinal amyloidosis - clinical features, diagnosis and therapy. Aliment Pharmacol Ther. 2008;27:1006-1016. [PMID: 18363891 DOI: 10.1111/j.1365-2036.2008.03682.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 48] [Article Influence: 5.0] [Reference Citation Analysis]
16 Dahiya DS, Kichloo A, Singh J, Albosta M, Wani F. Gastrointestinal amyloidosis: A focused review. World J Gastrointest Endosc 2021; 13(1): 1-12 [PMID: 33520102 DOI: 10.4253/wjge.v13.i1.1] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Mainenti PP, Camera L, Nicotra S, Cantalupo T, Soscia E, Vizio DD, Insabato G, Salvatore M. Splenic hypoperfusion as a sign of systemic amyloidosis. Abdom Imaging 2005;30:768-72. [DOI: 10.1007/s00261-005-0317-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Alloni A, Pellegrini C, Ragni T, Goggi C, D'Armini AM, Rinaldi M, Viganò M. Heart transplantation in patients with amyloidosis: single-center experience. Transplant Proc 2004;36:643-4. [PMID: 15110619 DOI: 10.1016/j.transproceed.2004.03.077] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
19 González de la Calle V, García-Sanz R, Mateos MV. [Primary amyloidosis]. Med Clin (Barc) 2016;147:121-6. [PMID: 27085744 DOI: 10.1016/j.medcli.2016.02.018] [Reference Citation Analysis]
20 Tawada A, Kanda T, Oide T, Tsuyuguchi T, Imazeki F, Nakatani Y, Yokosuka O. 18F-fluorodeoxyglucose positron emission tomography might be useful for diagnosis of hepatic amyloidosis. Int Med Case Rep J 2014;7:103-9. [PMID: 25018655 DOI: 10.2147/IMCRJ.S63296] [Reference Citation Analysis]
21 Norero B, Pérez-ayuso RM, Duarte I, Ramirez P, Soza A, Arrese M, Benítez C. Portal hypertension and acute liver failure as uncommon manifestations of primary amyloidosis. Annals of Hepatology 2014;13:142-9. [DOI: 10.1016/s1665-2681(19)30916-0] [Cited by in Crossref: 6] [Article Influence: 0.9] [Reference Citation Analysis]
22 Takayasu V, Laborda LS, Bernardelli R, Pinesi HT, Silva MP, Chiavelli V, Simões AB, Felipe-Silva A. Amyloidosis: an unusual cause of portal hypertension. Autops Case Rep 2016;6:9-18. [PMID: 27547738 DOI: 10.4322/acr.2016.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
23 Ericson S, Shah N, Liberman J, Aboulafia DM. Fatal Bleeding Due to Acquired Factor IX and X Deficiency: A Rare Complication of Primary Amyloidosis; Case Report and Review of the Literature. Clinical Lymphoma Myeloma and Leukemia 2014;14:e81-6. [DOI: 10.1016/j.clml.2013.08.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
24 Iwai M, Ishii Y, Mori T, Harada Y, Kitagawa Y, Kashiwadani M, Ou O, Okanoue T, Kashima K. Cholestatic jaundice in two patients with primary amyloidosis: ultrastructural findings of the liver. J Clin Gastroenterol 1999;28:162-6. [PMID: 10078828 DOI: 10.1097/00004836-199903000-00017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
25 Haddad MG, Silverman JF, Larkin EW, Dellasega M. Initial Diagnosis of Unsuspected Primary Amyloidosis (AL) by Liver Biopsy. Int J Surg Pathol 1993;1:57-63. [DOI: 10.1177/106689699300100108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
26 Kastritis E, Dimopoulos MA. Recent advances in the management of AL Amyloidosis. Br J Haematol 2016;172:170-86. [DOI: 10.1111/bjh.13805] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 9.2] [Reference Citation Analysis]
27 Kyle RA, Gertz MA. Systemic amyloidosis. Critical Reviews in Oncology/Hematology 1990;10:49-87. [DOI: 10.1016/1040-8428(90)90021-j] [Cited by in Crossref: 65] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
28 Briceño HC, Galván C, Segarra M, Calduch JV, García A, Ribón F. [Cholestatic jaundice and constitutional syndrome as early manifestations of primary systemic amyloidosis]. Gastroenterol Hepatol 2003;26:424-6. [PMID: 12887857 DOI: 10.1016/s0210-5705(03)70385-9] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
29 Takao S, Tanaka K, Miyazaki M, Tanaka M, Ohashi T, Kato M, Kotoh K, Aishima S, Takayanagi R. A case of fatal intrahepatic cholestasis with primary AL amyloidosis: is early diagnosis possible? Clin J Gastroenterol 2013;6:386-9. [PMID: 26181836 DOI: 10.1007/s12328-013-0406-x] [Reference Citation Analysis]
30 Hasan SM, Ahmed NN, Ahmed Z, Seibert A. Response of Bortezomib Chemotherapy in Hepatic Amyloidosis. J Investig Med High Impact Case Rep 2018;6:2324709618760079. [PMID: 29552568 DOI: 10.1177/2324709618760079] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Hashimoto O, Harada M, Sata M, Imamura K, Matsukuma N, Fukushima H, Itano S, Ohishi M, Ueno T, Iemura A, Kojiro M, Tanikawa K. Functional liver imaging with asialoglycoprotein receptors and serum hyaluronate in a patient with amyloidosis. J Gastroenterol 1995;30:403-7. [DOI: 10.1007/bf02347519] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
32 Malnick S, Melzer E, Sokolowski N, Basevitz A. The involvement of the liver in systemic diseases. J Clin Gastroenterol 2008;42:69-80. [PMID: 18097294 DOI: 10.1097/MCG.0b013e318135442e] [Cited by in Crossref: 29] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
33 Chen S, Kao C, Poon S. Radionuclide Imaging in Primary Amyloidosis with Liver Involvement: . Clinical Nuclear Medicine 1998;23:374-6. [DOI: 10.1097/00003072-199806000-00008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
34 Pozzi C, Locatelli F. Kidney and liver involvement in monoclonal light chain disorders. Seminars in Nephrology 2002;22:319-30. [DOI: 10.1053/snep.2002.33673] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
35 Dias T, Ferreira D, Moreira H, Nascimento T, Santos A, Carvalho A. A Case of Severe Cholestasis due to Hepatic AL Amyloidosis. GE Port J Gastroenterol 2019;26:425-9. [PMID: 31832498 DOI: 10.1159/000496185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
36 Casiraghi M, De Paoli A, Assi A, Palladini G, Lavazza M, Beretta A, Gualdoni G, Beretta R. Hepatic amyloidosis with light chain deposition disease. A rare association. Digestive and Liver Disease 2000;32:795-8. [DOI: 10.1016/s1590-8658(00)80358-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
37 Lovat LB, Persey MR, Madhoo S, Pepys MB, Hawkins PN. The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut 1998;42:727-34. [PMID: 9659172 DOI: 10.1136/gut.42.5.727] [Cited by in Crossref: 78] [Cited by in F6Publishing: 55] [Article Influence: 3.4] [Reference Citation Analysis]
38 Goldberg D, Weisberg I, Diuguid D, Gaglio P, Alobeid B, Fink S, Radhakrishnan J. Worth a second look. Am J Med 2009;122:24-6. [PMID: 19114166 DOI: 10.1016/j.amjmed.2008.09.015] [Reference Citation Analysis]
39 Hirano K, Ikemura M, Mizuno S, Tada M, Isayama H, Watanabe T, Saito T, Kawahata S, Uchino R, Hamada T. Two cases with hepatic amyloidosis suspected of having primary sclerosing cholangitis. Hepatol Res. 2013;43:911-916. [PMID: 23675805 DOI: 10.1111/hepr.12034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
40 Gertz MA, Kyle RA. Primary Systemic Amyloidosis—a Diagnostic Primer. Mayo Clinic Proceedings 1989;64:1505-19. [DOI: 10.1016/s0025-6196(12)65706-1] [Cited by in Crossref: 161] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
41 Sarsik B, Sen S, Kirdok FS, Akarca US, Toz H, Yilmaz F. Hepatic amyloidosis: Morphologic spectrum of histopathological changes in AA and nonAA amyloidosis. Pathology - Research and Practice 2012;208:713-8. [DOI: 10.1016/j.prp.2012.07.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
42 Mongin M, Disdier P, Swiader L, Harle J, Weiller P. Hématome sous-capsulaire hépatique spontané et syndrome inflammatoire. La Revue de Médecine Interne 1995;16:232s-4s. [DOI: 10.1016/0248-8663(96)80841-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
43 Nagra N, Burman B, Gault CR, Dorer R, Siddique A. Amyloidosis Masquerading as Alcohol-Related Cirrhosis. Cureus 2020;12:e8976. [PMID: 32775058 DOI: 10.7759/cureus.8976] [Reference Citation Analysis]
44 Peters RA, Koukoulis G, Gimson A, Portmann B, Westaby D, Williams R. Primary amyloidosis and severe intrahepatic cholestatic jaundice. Gut 1994;35:1322-5. [PMID: 7959246 DOI: 10.1136/gut.35.9.1322] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 1.5] [Reference Citation Analysis]
45 Bienz N, Franklin I, Adu D, Elias E, Mcmaster P, Hubscher S. Bilateral nephrectomy for uncontrollable nephrotic syndrome in primary amyloidosis, with subsequent improvement in hepatic function. Clinical & Laboratory Haematology 1994;16:85-8. [DOI: 10.1111/j.1365-2257.1994.tb00391.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
46 Cardoso BA, Leal R, Sá H, Campos M. Acute liver failure due to primary amyloidosis in a nephrotic syndrome: a swiftly progressive course. BMJ Case Rep 2016;2016:bcr2016214392. [PMID: 26965175 DOI: 10.1136/bcr-2016-214392] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
47 Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V. Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease. Haematologica. 2009;94:1029-1032. [PMID: 19454500 DOI: 10.3324/haematol.2008.001925] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
48 Loustaud-Ratti VR, Cypierre A, Rousseau A, Yagoubi F, Abraham J, Fauchais AL, Carrier P, Lefebvre A, Bordessoule D, Vidal E. Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool. Amyloid. 2011;18:19-24. [PMID: 21219116 DOI: 10.3109/13506129.2010.543443] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
49 Zhang L, Shen K, Zhang C, Qiu Y, Miao H, Feng J, Cao X, Zhang L, Zhou D, Li J. Clinical presentation and prognostic analysis of Chinese patients with systemic light chain amyloidosis with liver involvement. Leukemia Research 2019;86:106226. [DOI: 10.1016/j.leukres.2019.106226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Abraham RS, Geyer SM, Price-troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain–associated amyloidosis (AL). Blood 2003;101:3801-7. [DOI: 10.1182/blood-2002-09-2707] [Cited by in Crossref: 159] [Cited by in F6Publishing: 141] [Article Influence: 8.8] [Reference Citation Analysis]
51 Horsmans Y, Brenard R, Ferrant A, Lagneaux G, Geubel AP. Long-term favourable outcome of portal hypertension complicating primary systemic amyloidosis. Liver 1995;15:332-4. [PMID: 8609814 DOI: 10.1111/j.1600-0676.1995.tb00694.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
52 Clough J, Shah R. Primary Amyloidosis Presenting as Common Bile Duct Obstruction With Cholangitis. ACG Case Rep J. 2015;2:107-109. [PMID: 26157929 DOI: 10.14309/crj.2015.20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
53 Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore). 2003;82:291-298. [PMID: 14530778 DOI: 10.1097/01.md.0000091183.93122.c7] [Cited by in Crossref: 133] [Cited by in F6Publishing: 103] [Article Influence: 7.4] [Reference Citation Analysis]
54 Faa G, Van Eyken P, De Vos R, Fevery J, Van Damme B, De Groote J, Desmet VJ. Light chain deposition disease of the liver associated with AL-type amyloidosis and severe cholestasis. J Hepatol 1991;12:75-82. [PMID: 1901075 DOI: 10.1016/0168-8278(91)90913-v] [Cited by in Crossref: 34] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
55 Mainenti PP, Petrelli G, Lamanda R, Amalfi G, Castiglione F. Primary Systemic Amyloidosis With Giant Hepatomegaly and a Swiftly Progressive Course: . Journal of Clinical Gastroenterology 1997;24:173-5. [DOI: 10.1097/00004836-199704000-00011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
56 Kyle RA, Kelly JJ, Dyck PJ. Amyloidosis and Neuropathy. Peripheral Neuropathy. Elsevier; 2005. pp. 2427-51. [DOI: 10.1016/b978-0-7216-9491-7.50111-3] [Cited by in Crossref: 18] [Article Influence: 1.1] [Reference Citation Analysis]
57 Ferreira S, Baldaia C, Fatela N, Ramalho F, Adília Costa M, Brito D, Esteves G, Monteiro E. Severe intrahepatic cholestasis, erythrocytosis and hypoglycemia: Unusual presenting features of systemic AL amyloidosis. Scandinavian Journal of Gastroenterology 2009;43:375-9. [DOI: 10.1080/00365520701679298] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
58 Rosenzweig M, Kastritis E. Liver and Gastrointestinal Involvement: Update. Hematol Oncol Clin North Am 2020;34:e1-e13. [PMID: 33518015 DOI: 10.1016/j.hoc.2020.11.001] [Reference Citation Analysis]
59 Ebert EC, Nagar M. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol. 2008;103:776-787. [PMID: 18076735 DOI: 10.1111/j.1572-0241.2007.01669.x] [Cited by in Crossref: 178] [Cited by in F6Publishing: 134] [Article Influence: 12.7] [Reference Citation Analysis]
60 Caballeria J, Bruguera M, Sole M, Campistol JM, Rodes J. Hepatic familial amyloidosis caused by a new mutation in the apolipoprotein AI gene: clinical and pathological features. Am J Gastroenterology 2001;96:1872-6. [DOI: 10.1111/j.1572-0241.2001.03887.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
61 Guo YM, Takahashi N, Miyabe K, Yoshida M, Abe F, Yamashita T, Nara M, Yoshioka T, Ohashi K, Goto A, Takahashi N. Immunoglobulin Light Chain Amyloidosis with Severe Liver Dysfunction Accompanied by Factor X Deficiency. Intern Med 2019;58:3039-43. [PMID: 31243220 DOI: 10.2169/internalmedicine.2864-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Friedman S, Janowitz HD. SYSTEMIC AMYLOIDOSIS AND THE GASTROINTESTINAL TRACT. Gastroenterology Clinics of North America 1998;27:595-614. [DOI: 10.1016/s0889-8553(05)70022-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
63 Theodorakakou F, Fotiou D, Dimopoulos MA, Kastritis E. Solid Organ Transplantation in Amyloidosis. Acta Haematol 2020;143:352-64. [PMID: 32535598 DOI: 10.1159/000508262] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
64 Pascali E. Diagnosis and treatment of primary amyloidosis. Critical Reviews in Oncology/Hematology 1995;19:149-81. [DOI: 10.1016/1040-8428(94)00135-g] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
65 Shin YM. Hepatic amyloidosis. Korean J Hepatol 2011;17:80-3. [PMID: 21494083 DOI: 10.3350/kjhep.2011.17.1.80] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]